GoPath offers a full suite of genetic and genomic assays. Targeted NGS panels and cancer-specific custom gene panels provide a comprehensive analysis of well-characterized cancer genes that include:

 

• Molecular Genomic Profiling from FFPE Tissue Samples          

• Sequencing of the Entire Coding Region          

• Analysis of Rearrangements          

• Microsatellite Instability Analysis (MSI)  
• Cutting-Edge Bioinformatics Pipeline
• Tumor Mutational Burden (TMB) and iScore
• Neoantigen Prediction
• Liquid Biopsy (ctDNA)

 

• Immunophenotyping          

• Biomarker Analysis          

• Mutational Analysis that includes TMB and MSI analysis

• Immune gene expression analysis (IHC and proprietary RNA-seq panel to characterize the immune response) 

• CLIA-validated IHC/IF assays, pharmDx IHC/IF assays and IHC-based companion diagnostics for immunotherapies
• Strong history of LDT and companion diagnostic development

• On-site pathologists assist with optimization and standardization of new IHC/IF targets

• Develops custom IHC/IF assays and offers solutions to optimize existing IHC/IF assays

• Comprehensive collection of IHC/IF assays

• Consistently incorporates new IHC/IF assays with rapid validation times

• Use of fluorescence in situ hybridization (FISH) panels including:

          •   ALL panel (Acute Lymphoblastic Leukemia)
          •   AML panel (Acute Myeloid Leukemia)
          •   CLL panel (Chronic Lymphocytic Leukemia)
          •   CML probe (Chronic Myeloid Leukemia)
          •   MDS panel (Myelodysplastic Syndrome)
          •   MM panel (Multiple Myeloma)
          •   MPN panel (Myeloproliferative Neoplasia)
          •   NHL panel (Non-Hodgkins Lymphoma)
          •   T-Cell panel (Leukemia/Lymphoma)

• GoPath leverages cell-based assays and biomarker analysis in preclinical and translational Mechanism of  Action (MOA) studies

• We have a bank of more than 100 human tumor cell lines